Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01854047 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 776
- Enrollment target
NCT01854047: Completed Phase 2 study, sponsored by Sanofi.
NCT01854047 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 776 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (483% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01854047, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 776 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma. Secondary Objective: To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard to: * Safety and tolerability * Dupilumab systemic exposure and anti-drug antibodies
Primary Outcome
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Interventions
- DRUG placebo
- DRUG Dupilumab
- DRUG ICS/LABA therapy
- DRUG Salbutamol/albuterol
- DRUG Levosalbutamol/levalbuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 776 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
What the finished NCT01854047 record still lists
NCT01854047 is an interventional study that assigns participants to a tested intervention. The registered 776 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (483% higher).
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01854047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01854047 about?
NCT01854047 is a clinical study titled "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma". Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma. Secondary Objective: To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard...
What is the current status of trial NCT01854047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 776 participants. The study started on 2013-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01854047?
The interventions under investigation include: placebo (DRUG), Dupilumab (DRUG), ICS/LABA therapy (DRUG), Salbutamol/albuterol (DRUG), Levosalbutamol/levalbuterol (DRUG).
Who is sponsoring clinical trial NCT01854047?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01854047's enrollment target sits among peer trials
776 42nd of 2000 higher than 1,959 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06145763 · 776 participants · NA
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT03460769 · 775 participants
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia